Leverkusen — The global WuXi Biologics Group has acquired a sterile filling and freeze-drying plant from Bayer AG. The plant is designed for the filling and freeze-drying of the blood coagulant Kovaltry®. The plant is operated on the Chempark site in Leverkusen. WuXi was advised on this transaction by a team led by Dirk W. Kolvenbach of Heuking Kühn Lüer Wojtek.
Under the asset purchase agreement signed in January, WuXi Biologics took over plant operations, purchased plant equipment and signed a long-term construction lease. Equipped with a state-of-the-art filling line for pharmaceutical products, the plant will offer sterile filling and freeze-drying of up to ten million vials per year.
“We are pleased to enter into this significant agreement with Bayer and to establish our second site in Europe,” said Dr. Chris Chen, CEO of WuXi Biologics. “With this new facility in Germany, we can better serve our global customers by implementing the unique manufacturing paradigm of ‘global dual sourcing’ through our robust and high-quality supply chain. We will continue to enable our global partners to develop and manufacture biologics that benefit patients worldwide.”
WuXi Biologics is a leading global open access technology platform for biologics. The company provides end-to-end solutions to help companies discover, develop and manufacture biologics from concept to commercial production. To support the fight against COVID-19, WuXi Biologics has donated more than 1,600 masks to medical facilities in Leverkusen, Germany.
Advisor to WuXi Biologics: Heuking Kühn Lüer Wojtek
Dirk W. Kolvenbach, Photo (lead) Düsseldorf, Michael Pauli, LL.M. (Corporate), Cologne; Wolfram Meven, Jörn Matuszewski (both Tax), Dr. Rainer Velte (Antitrust), Düsseldorf; Fabian Gerstner, LL.M., Bettina Neheider (both Construction Law), both Munich; Christoph Nöhles, LL.M., Mathis Dick, LL.M. (both Real Estate), both Düsseldorf
Dr. Bodo Dehne (Investment Control), Dr. Tobias Plath, LL.M. (Insurance Law), Torsten Groß, LL.M. (Labor Law), Sarah Radon, LL.M. (Commercial)
Advisors to Bayer: Redeker Sellner Dahs
Dr. Markus Dierksmeier (Corporate), Bartholomäus Aengenvoort, Alexander Leidig (both Real Estate), all Bonn